Skip Navigation



JAC Advance Access published online on July 1, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg323
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/306    most recent
dkg323v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cynamon, M. H.
Right arrow Articles by Yeo, A. E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cynamon, M. H.
Right arrow Articles by Yeo, A. E. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection

Michael H. Cynamon 1 *, Shannon A. Elliott 1 , Michelle S. DeStefano 1 , and Anthony E. T. Yeo 2

1 Department of Medicine, Veterans Affairs Medical Center, 800 Irving Avenue, Syracuse, NY 13210
2 Jacobus Pharmaceutical Company Inc., Princeton, NJ, USA

* Corresponding author. E-mail: Michael.Cynamon{at}med.VA.gov.

Received 29 October 2002 ; accepted 9 May 2003

Abstract

Activities of clarithromycin alone and in combination with rifampicin, gatifloxacin or linezolid were evaluated against Mycobacterium kansasii in a murine infection model. Clarithromycin was the most active single agent. Rifampicin and gatifloxacin had similar activities, but were less active than clarithromycin. Clarithromycin in combination with rifampicin was the most active combination therapy.

Keywords: clarithromycin, chemotherapy, combination therapy, M. kansasii, murine infection model, mycobacteria
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Santin, J. Dorca, F. Alcaide, L. Gonzalez, S. Casas, M. Lopez, and M. R. Guerra
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease
Eur. Respir. J., January 1, 2009; 33(1): 148 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. W. Wieland, S. Florquin, J. M. Pater, S. Weijer, and T. van der Poll
CD4+ Cells Play a Limited Role in Murine Lung Infection with Mycobacterium kansasii
Am. J. Respir. Cell Mol. Biol., February 1, 2006; 34(2): 167 - 173.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Guna, C. Munoz, V. Dominguez, A. Garcia-Garcia, J. Galvez, J.-V. de Julian-Ortiz, and R. Borras
In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii
J. Antimicrob. Chemother., June 1, 2005; 55(6): 950 - 953.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.